25th Feb 2026 Plain language summary of pegcetacoplan therapy in kidney transplant patients with C3G or primary IC-MPGN from the NOBLE study
25th Feb 2026 Plain language summary of sparsentan clinical trial findings in patients with focal segmental glomerulosclerosis
25th Feb 2026 Long-term outcomes of atacicept therapy in IgA nephropathy patients: a plain language summary
22nd Sep 2025 LOCK IT-100 study: A plain language summary of the taurolidine/heparin catheter lock solution
16th Sep 2025 Plain language summary: Global Registry data shows patients with aHUS can safely and effectively change from eculizumab to ravulizumab treatment
28th Aug 2025 Examining empagliflozin’s safety profile across four clinical trials: a plain language summary
25th Jun 2025 Plain language summary: benefits of SGLT2 inhibitor medications for people living with chronic kidney disease
24th Feb 2025 Plain language summary: effectiveness and safety of gepotidacin, a new oral antibiotic, versus nitrofurantoin, a commonly used antibiotic, for treating uncomplicated urinary tract infections
11th Feb 2025 A plain language summary of a study on long-term outcomes in IgA nephropathy patients from the UK Rare Kidney Diseases Registry (RaDaR)
17th Jan 2025 Evaluating tenapanor for managing hyperphosphatemia in dialysis patients: a plain language summary of the OPTIMIZE study
22nd Jan 2024 The TITAN study: a plain language summary looking at how PSA decline with apalutamide therapy is associated with longer survival and improved outcomes in people with metastatic prostate cancer
18th Jan 2024 Plain language summary: looking at the enfortumab vedotin plus pembrolizumab treatment combination for untreated locally advanced or metastatic urothelial cancer
17th Jan 2024 Relugolix combination therapy for the treatment of pain associated endometriosis: a plain language summary
3rd Nov 2023 A plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with a long term follow-up
13th Sep 2023 The effect of vibegron on the blood pressure and heart rate in people with overactive bladder: a plain language summary
25th Nov 2022 Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?
25th Nov 2022 Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?
20th Sep 2022 Plain language summary of a study looking at heart muscle thickness and kidney function in women with Fabry disease who received agalsidase beta treatment
22nd Aug 2022 Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer
28th Jul 2022 A plain language summary of the likelihood of symptom relief for patients taking fesoterodine for overactive bladder
15th Jun 2022 Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial
20th May 2022 Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer
9th Feb 2021 Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial
